After successful completion of Phase I established initial Mitogard stability and drug safety for the new intrathecal route for cyclosporin, the amount of $894,000 for year two was released by the National Institutes of Health.
According to the company, Phase II will complete the preclinical stability, toxicology and pharmacokinetics over the next two years to enable the first human clinical trials for Maas Biolab’s Mitogard intrathecal cyclosporin formula designed for the treatment of amyotrophic lateral sclerosis (ALS).
Jenny Karlsson, director of preclinical development at Maas, said: “The first year’s results show Mitogard intrathecal safety in the therapeutic range, and we look forward with excitement to the second year’s more in-depth toxicology testing.”